The primary objective of this review article is to provide a coherent, systematic synthesis of the literature on the management of suicidality in schizophrenia that is relevant to the front-line clinician.
Method
Literature searches were conducted on MEDLINE (1996 to 2007) and PubMed (1993 to 2007), using the key words “schizophrenia” and “suicide,” as well as references from the resulting articles. I used my own clinical experience to create fictional case examples to illustrate the applicability of the literature discussed in this paper.
Results
Suicidality in schizophrenia is high, and early detection relies on the appreciation and evaluation of the clinical manifestations of depression, despair, and hopelessness, as well as on the nature and severity of the psychotic experience itself, particularly in recent-onset patients with higher cognitive function and educational background. Clinical management includes ensuring immediate safety, the use of psychosocial techniques to address depression and psychosocial stressors, targeted pharmacotherapy for depression and psychosis, and adequate discharge planning. Clozapine is the only antipsychotic with good evidence for efficacy in decreasing suicidal behaviour in schizophrenia.
Conclusions
The optimal management of suicidality in schizophrenia involves the incorporation of traditional bedside clinical skills, selection of psychosocial modalities based on individual needs, and selective pharmacotherapy directed primarily at psychotic and depressive symptoms.
AuquierP, LanconC, RouillonF, . Mortality in schizophrenia. Pharmacoepidemiol Drug Saf. 2006;15:873–879.
2.
GuptaS, BlackDW, ArndtS, . Factors associated with suicide attempts among patients with schizophrenia. Psychiatr Serv. 1998;49:1353–1355.
3.
InskipHM, HarrisEC, BarracloughB.Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry. 1998;172:35–37.
4.
CaldwellCB, GottesmanII.Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull. 1990;16:571–589.
5.
WinokurG, TsuangM.The Iowa 500: suicide in mania, depression, and schizophrenia. Am J Psychiatry. 1975;132:650–651.
6.
PalmerBA, PankratzVS, BostwickJM.The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62:247–253.
7.
KimCH, JayathilakeK, Meltzer Hopelessness HY., neurocognitive function, and insight in schizophrenia: relationship to suicidal behaviour. Schizophr Res. 2003;60:71–80.
8.
RadomskyED, HaasGL, MannJJ, . Suicidal behaviour in patients with schizophrenia and other psychotic disorders. Am J Psychiatry. 1999;156:1590–1595.
9.
McGlashanTH.The Chestnut Lodge follow-up study. II. Long-term outcome of schizophrenia and the affective disorders. Arch Gen Psychiatry. 1984;41:586–601.
10.
MorganHG, PriestP.Suicide and other unexpected deaths among psychiatric in-patients. The Bristol confidential inquiry. Br J Psychiatry. 1991;158:368–374.
11.
BurgessP, PirkisJ, MortonJ, . Lessons from a comprehensive clinical audit of users of psychiatric services who committed suicide. Psychiatr Serv. 2000;51:1555–1560.
12.
PompiliM, MancinelliI, GirardiP, . Nursing schizophrenic patients who are at risk of suicide. J Psychiatr Ment Health Nurs. 2003;10:622–624.
13.
BhatiaMS, AggarwalNK, AggarwalBB.Psychosocial profile of suicide ideators, attempters and completers in India. Int J Soc Psychiatry. 2000;46:155–163.
14.
BeautraisAL.Suicides and serious suicide attempts: two populations or one? Psychol Med. 2001;31:837–845.
15.
RossauCD, MortensenPB.Risk factors for suicide in patients with schizophrenia: nested case-control study. Br J Psychiatry. 1997;171:355–359.
16.
LesterD.Sex differences in completed suicide by schizophrenic patients: a meta-analysis. Suicide Life Threat Behav. 2006;36:50–56.
17.
HuntIM, KapurN, WindfuhrK, . Suicide in schizophrenia: findings from a national clinical survey. J Psychiatr Pract. 2006;12:139–147.
18.
HeilaH, IsometsaET, HenrikssonMM, . Antecedents of suicide in people with schizophrenia. Br J Psychiatry. 1998;173:330–333.
PokornyAD.Prediction of suicide in psychiatric patients. Report of a prospective study. Arch Gen Psychiatry. 1983;40:249–257.
21.
BlackST, LesterD.Distinguishing suicide notes from completed and attempted suicides. Percept Mot Skills. 1995;81:(3 Pt 1)802.
22.
ApplebyL, ShawJ, AmosT, . Suicide within 12 months of contact with mental health services: national clinical survey. BMJ. 1999;318:1235–1239.
23.
FialkoL, FreemanD, BebbingtonPE, . Understanding suicidal ideation in psychosis: findings from the Psychological Prevention of Relapse in Psychosis (PRP) trial. Acta Psychiatr Scand. 2006;114:177–186.
24.
WilliamsJ.Cry of pain: understanding suicide and self-harm. London (GB): Penguin;1997.
25.
AcostaFJ, AguilarEJ, CejasMR, . Are there subtypes of suicidal schizophrenia? A prospective study. Schizophr Res. 2006;86:215–220.
26.
McGirrA, TousignantM, RouthierD, . Risk factors for completed suicide in schizophrenia and other chronic psychotic disorders: a case-control study. Schizophr Res. 2006;84:132–143.
27.
FentonWS, McGlashanTH, VictorBJ, . Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry. 1997;154:199–204.
28.
MannJJ.A current perspective of suicide and attempted suicide. Ann Intern Med. 2002;136:302–311.
29.
HawtonK, SuttonL, HawC, . Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005;187:9–20.
30.
HeilaH, IsometsaET, HenrikssonMM, . Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry. 1997;154:1235–1242.
31.
MortensenPB, JuelK.Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry. 1993;163:183–189.
32.
FunahashiT, IbukiY, DomonY, . A clinical study on suicide among schizophrenics. Psychiatry Clin Neurosci. 2000;54:173–179.
33.
SirisSG.Suicide and schizophrenia. J Psychopharmacol. 2001;15:127–135.
34.
Cunningham OwensDG, CarrollA, FattahS, . A randomized, controlled trial of a brief interventional package for schizophrenic out-patients. Acta Psychiatr Scand. 2001;103:362–369.
35.
KuoCJ, TsaiSY, LoCH, . Risk factors for completed suicide in schizophrenia. J Clin Psychiatry. 2005;66:579–585.
36.
NangleJM, ClarkeS, MorrisDW, . Neurocognition and suicidal behaviour in an Irish population with major psychotic disorders. Schizophr Res. 2006;85:196–200.
37.
PotkinSG, AlphsL, HsuC, . Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. Biol Psychiatry. 2003;54:444–452.
38.
UcokA, TukelR, OzgenG, . [Frequency of obsessive compulsive symptoms and disorder in patients with schizophrenia: importence for prognosis]. Encephale. 2006;32:(1 Pt 1)41–44.
39.
SevincokL, AkogluA, KokcuF.Suicidality in schizophrenic patients with and without obsessive-compulsive disorder. Schizophr Res. 2007;90:198–202.
40.
BhatiaT, ThomasP, SemwalP, . Differing correlates for suicide attempts among patients with schizophrenia or schizoaffective disorder in India and USA. Schizophr Res. 2006;86:208–214.
41.
AltamuraAC, MundoE, BassettiR, . Transcultural differences in suicide attempters: analysis on a high-risk population of patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2007;89:140–146.
42.
PompiliM, MancinelliI, RubertoA, . Where schizophrenic patients commit suicide: a review of suicide among inpatients and former inpatients. Int J Psychiatry Med. 2005;35:171–190.
43.
NordentoftM, JeppesenP, AbelM, . OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis. One-year follow-up of a randomised controlled trial. Br J Psychiatry Suppl. 2002;43: s98–s106.
44.
BeckAT, SteerRA, KovacsM, . Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Am J Psychiatry. 1985;142:559–563.
45.
CohenLJ, TestMA, BrownRL.Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry. 1990;147:602–607.
46.
CiprianiA, PrettyH, HawtonK, . Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry. 2005;162:1805–1819.
47.
LeuchtS, Heres Epidemiology S., clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006;67:(Suppl 5)3–8.
48.
LehmanAF, LiebermanJA, DixonLB, . Practice guideline for the treatment of patients with schizophrenia, 2nd ed. Am J Psychiatry. 2004;161:(2 Suppl)1–56.
LaurielloJ, LenrootR, BustilloJR.Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia. Psychiatr Clin North Am. 2003;26:191–211.
51.
GraweRW, FalloonIR, WidenJH, . Two years of continued early treatment for recent-onset schizophrenia: a randomised controlled study. Acta Psychiatr Scand. 2006;114:328–336.
52.
WardA, IshakK, ProskorovskyI, . Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther. 2006;28:1912–1921.
53.
TurkingtonD, KingdonD, TurnerT.Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia. Br J Psychiatry. 2002;180:523–527.
54.
TarrierN, HaddockG, LewisS, . Suicide behaviour over 18 months in recent onset schizophrenic patients: the effects of CBT. Schizophr Res. 2006;83:15–27.
55.
TurkingtonD, DudleyR, WarmanDM, . Cognitive-behavioural therapy for schizophrenia: a review. J Psychiatr Pract. 2004;10:5–16.
56.
JonesC, CormacI, Silveirada Mota Neto JI, et al. Cognitive behaviour therapy for schizophrenia. Cochrane Database Syst Rev.2004;(4):CD000524.
57.
BustilloJ, LaurielloJ, HoranW, . The psychosocial treatment of schizophrenia: an update. Am J Psychiatry. 2001;158:163–175.
58.
MalmbergL, FentonM.Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness. Cochrane Database Syst Rev.2001;(3):CD001360.
59.
StantonAH, GundersonJG, KnappPH, . Effects of psychotherapy in schizophrenia: I. Design and implementation of a controlled study. Schizophr Bull. 1984;10:520–563.
60.
LeePW, Lieh-MakF, WongMC, . The 15-year outcome of Chinese patients with schizophrenia in Hong Kong. Can J Psychiatry. 1998;43:706–713.
61.
AmadorXF, FriedmanJH, KasapisC, . Suicidal behaviour in schizophrenia and its relationship to awareness of illness. Am J Psychiatry. 1996;153:1185–1188.
62.
CrumlishN, WhittyP, KamaliM, . Early insight predicts depression and attempted suicide after 4 years in first-episode schizophrenia and schizophreniform disorder. Acta Psychiatr Scand. 2005;112:449–455.
63.
BourgeoisM, SwendsenJ, YoungF, . Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial. Am J Psychiatry. 2004;161:1494–1496.
64.
LehmanAF, BuchananRW, DickersonFB, . Evidence-based treatment for schizophrenia. Psychiatr Clin North Am. 2003;26:939–954.
65.
ErnstCL, GoldbergJF.Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry. 2004;12:14–41.
66.
MeltzerHY.Treatment of suicidality in schizophrenia. Ann N Acad Y Sci.2001;932:44–58.; discussion 58-60.
67.
CohenS, LeonardCV, FarberowNL, . Tranquilizers and Suicide in the Schizophrenic Patient. Arch Gen Psychiatry. 1964;11:312–321.
68.
WarnesH.Suicide in schizophrenics. Dis Nerv Syst. 1968;29:(Suppl)35–40.
69.
RoyA.Suicide in chronic schizophrenia. Br J Psychiatry. 1982;141:171–177.
70.
TaiminenTJ, KujariH.Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. A controlled retrospective study. Acta Psychiatr Scand. 1994;90:247–251.
71.
TaiminenTJ.Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients. Acta Psychiatr Scand. 1993;87:45–47.
72.
HoganTP, AwadAG.Pharmacotherapy and suicide risk in schizophrenia. Can J Psychiatry. 1983;28:277–281.
73.
ChengKK, LeungCM, LoWH, . Risk factors of suicide among schizophrenics. Acta Psychiatr Scand. 1990;81:220–224.
74.
PalmerDD, HenterID, WyattRJ.Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? J Clin Psychiatry.1999;60:(Suppl 2)100–103; discussion 111-106.
75.
WilkinsonG, BaconNA.A clinical and epidemiological survey of parasuicide and suicide in Edinburgh schizophrenics. Psychol Med. 1984;14:899–912.
76.
JohnsonDA, PasterskiG, LudlowJM, . The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand. 1983;67:339–352.
77.
CiompiL.Late suicide in former mental patients. Psychiatr Clin (Basel). 1976;9(1):59–63.
78.
MeltzerHY, OkayliG.Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry. 1995;152:183–190.
79.
SoloffPH, GeorgeA, NathanRS, . Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry. 1986;43:691–697.
80.
CowdryRW, GardnerDL.Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111–119.
81.
BattagliaJ, WolffTK, Wagner-JohnsonDS, . Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department. Int Clin Psychopharmacol. 1999;14:361–372.
82.
HeilaH, IsometsaET, HenrikssonMM, . Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. J Clin Psychiatry. 1999;60:200–208.
DrakeRE, EhrlichJ.Suicide attempts associated with akathisia. Am J Psychiatry. 1985;142:499–501.
85.
ShearMK, FrancesA, WeidenP.Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol. Aug1983;3:235–236.
86.
MamoDC, SweetRA, KeshavanMS.Managing antipsychotic-induced parkinsonism. Drug Saf. 1999;20:269–275.
87.
MeltzerHY.Suicide and schizophrenia: clozapine and the Inter Se PT study. International Clozaril/Leponex Suicide Prevention Trial. J Clin Psychiatry.1999;60Suppl 12:47–50.
88.
AltamuraAC, BassettiR, BignottiS, . Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res. 2003;60:47–55.
89.
SpivakB, MesterR, WittenbergN, . Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients. Clin Neuropharmacol. 1997;20:442–446.
90.
WalkerAM, LanzaLL, ArellanoF, . Mortality in current and former users of clozapine. Epidemiology. 1997;8:671–677.
91.
MeltzerHY, AlphsL, GreenAI, . Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82–91.
92.
ReidWH, MasonM, HoganT.Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv. 1998;49:1029–1033.
93.
SernyakMJ, DesaiR, StolarM, . Impact of clozapine on completed suicide. Am J Psychiatry. 2001;158:931–937.
94.
ErtugrulA.Clozapine and suicide. Am J Psychiatry. 2002;159:323; author reply 324.
95.
KhanA, KhanSR, LeventhalRM, . Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry. 2001;158:1449–1454.
96.
StorosumJG, van ZwietenBJ, WohlfarthT, . Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. Arch Gen Psychiatry. 2003;60:365–368.
97.
TranPV, HamiltonSH, KuntzAJ, . Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17:407–418.
98.
GlazerWM.Formulary decisions and health economics. J Clin Psychiatry. 1998;59:(Suppl 19)23–29.
99.
SakinofskyI, HeilaH, KrishnanR.Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia. Schizophr Bull. 2004;30:587–598.
100.
DugganA, WarnerJ, KnappM, . Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br J Psychiatry. 2003;182:505–508.
101.
FontaineKR, HeoM, HarriganEP, . Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101:277–288.
102.
SirisSG, MorganV, FagerstromR, . Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial. Arch Gen Psychiatry. 1987;44:533–539.
103.
SirisSG, BermanzohnPC, MasonSE, . Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry. 1994;51:109–115.
104.
WhiteheadC, MossS, CardnoA, . Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev.2002(2):CD002305.
105.
AddingtonD, AddingtonJ, PattenS, . Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol. 2002;22:20–25.
106.
GinsbergDL, SchoolerNR, BuckleyPF, . Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning. CNS Spectr. 2005;10:1–13.; discussion 14-15.
107.
FinkM, SackeimHA.Convulsive therapy in schizophrenia? Schizophr Bull. 1996;22:27–39.
108.
MelleI, JohannesenJO, FriisS, . Early detection of the first episode of schizophrenia and suicidal behaviour. Am J Psychiatry. 2006;163:800–804.
109.
MarshallM, RathboneJ.Early intervention for psychosis. Cochrane Database Syst Rev.2006;(4):CD004718.
